EODData

MEMBERSHIP REGISTER LOG IN

ASX, IMM: Immutep Ltd.

28 Nov 2025
LAST:

0.3050

CHANGE:
 0.02		OPEN:
0.2850		HIGH:
0.3100		ASK:
0.2550		VOLUME:
5.09M
CHG(%):
5.56		PREV:
0.2700		LOW:
0.2850		BID:
0.2500		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Nov 250.28500.31000.28500.30505.09M
27 Nov 250.28000.29250.28000.28501.91M
26 Nov 250.27000.28000.27000.27001.6M
25 Nov 250.26500.27500.26500.26501.01M
24 Nov 250.25500.27000.25500.26001.15M
21 Nov 250.26000.26500.25500.26002.04M
20 Nov 250.25500.26500.25500.2650815.6K
19 Nov 250.27000.27500.26000.26001.17M
18 Nov 250.28000.28000.27000.27501.48M
17 Nov 250.28000.28500.27500.28003.65M

PROFILE

Name:Immutep Ltd.
About:Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:Australia Square, Sydney, NSW, Australia, 2000
Website:https://www.immutep.com
ISIN:AU000000IMM6
FIGI:BBG000BLY789

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-7.58 
Forward P/E:-5.40 
Price to Sales:78.79 
Price to Book:2.76 
Operating Margin:-20.35 
Return on Assets:-0.23 
Return on Equity:-0.37 
EPS Ratio:-0.04 
Revenue:5.04M 
Shares:1.468B 
Market Cap:447.7M 

TECHNICAL INDICATORS

MA5:0.2713.8%
MA10:0.2713.2%
MA20:0.2714.1%
MA50:0.2810.3%
MA100:0.2615.5%
MA200:0.2713.3%
STO9:76.92
STO14:80.00 
RSI14:65.00 
MTM14:0.03
ROC14:0.12 
ATR:0.01 
Week High:0.294.3%
Week Low:0.2619.6%
Month High:0.301.7%
Month Low:0.2513.3%
Year High:0.3926.2%
Year Low:0.2237.1%
Volatility:19.16 

RECENT SPLITS

Date Ratio
04 Nov 20191-10
01 Jun 20011-3